{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RPC-1063&page=2",
    "query": {
      "intervention": "RPC-1063",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RPC-1063&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-19T11:10:26.276Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05528666",
      "title": "Risk Perception in Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "High Efficacy Therapy (HET)",
          "type": "OTHER"
        },
        {
          "name": "Non High Efficacy Therapy (Non-HET)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 4361,
      "start_date": "2021-09-09",
      "completion_date": "2021-09-17",
      "has_results": false,
      "last_update_posted_date": "2022-11-08",
      "last_synced_at": "2026-09-19T11:10:26.276Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05528666"
    },
    {
      "nct_id": "NCT06334094",
      "title": "Assessing the Cognitive Benefits of Ozanimod and Their Brain-Biomarkers in MS",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Ozanimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas at Dallas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2024-06-01",
      "completion_date": "2028-05-31",
      "has_results": false,
      "last_update_posted_date": "2024-08-09",
      "last_synced_at": "2026-09-19T11:10:26.276Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06334094"
    },
    {
      "nct_id": "NCT05470985",
      "title": "A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Crohn Disease"
      ],
      "interventions": [
        {
          "name": "Ozanimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 5,
      "start_date": "2023-08-22",
      "completion_date": "2024-09-13",
      "has_results": true,
      "last_update_posted_date": "2025-04-22",
      "last_synced_at": "2026-09-19T11:10:26.276Z",
      "location_count": 19,
      "location_summary": "Garden Grove, California • Los Angeles, California • Sacramento, California + 15 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05470985"
    },
    {
      "nct_id": "NCT03464097",
      "title": "A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn Disease"
      ],
      "interventions": [
        {
          "name": "Ozanimod",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 550,
      "start_date": "2018-06-27",
      "completion_date": "2024-10-03",
      "has_results": true,
      "last_update_posted_date": "2025-10-09",
      "last_synced_at": "2026-09-19T11:10:26.276Z",
      "location_count": 188,
      "location_summary": "Peoria, Arizona • Scottsdale, Arizona • North Little Rock, Arkansas + 140 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "North Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Camarillo",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03464097"
    },
    {
      "nct_id": "NCT05953402",
      "title": "A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 1182,
      "start_date": "2026-04-21",
      "completion_date": "2034-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-15",
      "last_synced_at": "2026-09-19T11:10:26.276Z",
      "location_count": 1,
      "location_summary": "Wilmington, North Carolina",
      "locations": [
        {
          "city": "Wilmington",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05953402"
    },
    {
      "nct_id": "NCT05001152",
      "title": "Taste Assessment of Ozanimod",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Ozanimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "25 Years to 80 Years"
      },
      "enrollment_count": 7,
      "start_date": "2021-09-09",
      "completion_date": "2021-09-27",
      "has_results": false,
      "last_update_posted_date": "2023-06-18",
      "last_synced_at": "2026-09-19T11:10:26.276Z",
      "location_count": 2,
      "location_summary": "Woburn, Massachusetts",
      "locations": [
        {
          "city": "Woburn",
          "state": "Massachusetts"
        },
        {
          "city": "Woburn",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05001152"
    },
    {
      "nct_id": "NCT06529406",
      "title": "Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Relapsing Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Ozanimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2024-07-29",
      "completion_date": "2029-08-01",
      "has_results": false,
      "last_update_posted_date": "2025-09-18",
      "last_synced_at": "2026-09-19T11:10:26.276Z",
      "location_count": 3,
      "location_summary": "Aurora, Colorado • Las Vegas, Nevada • Cleveland, Ohio",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06529406"
    },
    {
      "nct_id": "NCT04149678",
      "title": "Drug Interaction Study of the Effect on Cyclosporine on Ozanimod and Major Active Metabolites",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Ozanimod",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 40,
      "start_date": "2019-10-04",
      "completion_date": "2019-12-26",
      "has_results": false,
      "last_update_posted_date": "2020-08-24",
      "last_synced_at": "2026-09-19T11:10:26.276Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04149678"
    },
    {
      "nct_id": "NCT02047734",
      "title": "Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsing Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Ozanimod",
          "type": "DRUG"
        },
        {
          "name": "Ozanimod placebo",
          "type": "DRUG"
        },
        {
          "name": "Interferon beta-1a",
          "type": "DRUG"
        },
        {
          "name": "Interferon beta-1a placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 1320,
      "start_date": "2013-12-03",
      "completion_date": "2017-04-13",
      "has_results": true,
      "last_update_posted_date": "2021-02-11",
      "last_synced_at": "2026-09-19T11:10:26.276Z",
      "location_count": 35,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 17 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02047734"
    },
    {
      "nct_id": "NCT03440385",
      "title": "Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn Disease"
      ],
      "interventions": [
        {
          "name": "Ozanimod",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 606,
      "start_date": "2018-03-07",
      "completion_date": "2023-11-21",
      "has_results": true,
      "last_update_posted_date": "2024-12-05",
      "last_synced_at": "2026-09-19T11:10:26.276Z",
      "location_count": 81,
      "location_summary": "Scottsdale, Arizona • La Jolla, California • Lancaster, California + 67 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03440385"
    }
  ]
}